**FDA Secondary and Comparative Claims and Biosimilars Disclosure Study**

**Study 1 Screener – Secondary and Comparative Claims**

**[Intro screen 1 - Website]**

[**DISPLAY]**

On the next screen, we will ask you to look at a picture of a website for a new prescription drug. Drug names have been changed for this survey.

A few tips when taking this survey:

Please make sure you are comfortable and can read the screen from where you sit.

You may have to scroll to see all of the information on the website.

**Take as much time as you need reading the information on the page.** Once you advance past the website to the survey questions, you will not be able to return to it.

**[PROGRAMMER: Display website corresponding to the participant’s experimental condition:**

**IF COHORT = 1 ‘Consumer’ AND XCONDITION = 1 ‘+ Comparative claim present, Disclosure 1, DISPLAY IMAGE: S1\_Cons\_1.jpg**

**IF COHORT = 1 ‘Consumer’ AND XCONDITION = 2 ‘Disclosure 2 + Comparative claim present’, DISPLAY IMAGE: S1\_Cons\_2. jpg**

**IF COHORT = 1 ‘Consumer’ AND XCONDITION = 3 ‘****Disclosure 3 + Comparative claim present’, DISPLAY IMAGE: S1\_Cons\_3. jpg**

**IF COHORT = 1 ‘Consumer’ AND XCONDITION = 4 ‘Disclosure 1 + Comparative claim present’, DISPLAY IMAGE: S1\_Cons\_4.jpg**

**IF COHORT = 1 ‘Consumer’ AND XCONDITION = 5 ‘Disclosure 2 + Comparative claim absent’, DISPLAY IMAGE: S1\_Cons\_5. jpg**

**IF COHORT = 1 ‘Consumer’ AND XCONDITION = 6 ‘Disclosure 3 + Comparative claim absent’, DISPLAY IMAGE: S1\_Cons\_6. jpg**

**IF COHORT = 1 ‘Consumer’ AND XCONDITION = 7 ‘Secondary claim only’, DISPLAY IMAGE: S1\_Cons\_7. jpg**

**IF COHORT = 1 ‘****HCP’ AND XCONDITION = 1 ‘Disclosure 1 + Comparative claim present, DISPLAY IMAGE: S1\_HCP\_1.jpg**

**IF COHORT = 1 ‘HCP’ AND XCONDITION = 2 ‘Disclosure 2 + Comparative claim present’, DISPLAY IMAGE: S1\_HCP \_2. jpg**

**IF COHORT = 1 ‘HCP’ AND XCONDITION = 3 ‘Disclosure 3 + Comparative claim present’, DISPLAY IMAGE: S1\_HCP\_3. jpg**

**IF COHORT = 1 ‘HCP’ AND XCONDITION = 4 ‘Disclosure 1 + Comparative claim present’, DISPLAY IMAGE: S1\_HCP\_4.jpg**

**IF COHORT = 1 ‘HCP’ AND XCONDITION = 5 ‘Disclosure 2 + Comparative claim absent’, DISPLAY IMAGE: S1\_HCP\_5. jpg**

**IF COHORT = 1 ‘HCP’ AND XCONDITION = 6 ‘Disclosure 3 + Comparative claim absent’, DISPLAY IMAGE: S1\_HCP\_6. jpg**

**IF COHORT = 1 ‘HCP’ AND XCONDITION = 7 ‘Secondary claim only’, DISPLAY IMAGE: S1\_HCP\_7. jpg**

**[Please disable the “Next” button for 5 seconds]**

*Please click the ‘Next’ button to continue. Once you leave this screen you will not be able to return to it.*

**[----------------------------------------New screen----------------------------------------]**

**[Show Website]**

**[----------------------------------------New screen----------------------------------------]**

Q1. Were you able to view the website?

**[SINGLE PUNCH]**

1 Yes

2 No **[TERMINATE; DISPLAY ‘Thank and Terminate’]**

[**PROGRAMMER:** For remaining questions, if respondent does not provide response, prompt with, “Are you sure you don’t want to provide a response?” before allowing to continue.]

**[----------------------------------------New screen----------------------------------------]**

[**Intro screen 2 - Survey]**

Now, please answer the following questions **based on the information you saw on the website.**

**[----------------------------------------New screen----------------------------------------]**

**[BENEFIT RECALL]**

Q2. What are the benefits of DRUG X? Please list as many benefits as you can remember.

[Open Field]

**[----------------------------------------New screen----------------------------------------]**

**[SECONDARY CLAIM/DISCLOSURE RECOGNITION]**

**[MULTIPLE PUNCH]**

Q3.This question asks about information that may or may not have been in the DRUG X website.

Which of these statements, if any, were on the website? *If you think a statement was mentioned on the website, click on that box to select it.* *Select all that apply*.

**[PROGRAMMER: RANDOMIZE ORDER OF ITEMS]**

|  | Mentioned on the website | Not mentioned on the website |
| --- | --- | --- |
| Q3\_a. DRUG X can give assistance in lowering A1C | 1 | 2 |
| Q3\_b. DRUG X may provide additional benefit of weight loss. | 1 | 2 |
| Q3\_c. In a clinical trial, adults with an average starting weight of 197 pounds lost around 12 pounds on DRUG X compared to 4 pounds on DRUG Y. | 1 | 2 |
| Q3\_d. DRUG X is not made for weight loss. | 1 | 2 |
| Q3\_e. DRUG X could also help some people lose some weight. | 1 | 2 |
| Q3\_f. DRUG X can help reduce the risk of cardiovascular death. | 1 | 2 |
| Q3\_g. DRUG X is for adults and children 10 years of age and older with type 2 diabetes. | 1 | 2 |

**[----------------------------------------New screen----------------------------------------]**

**[PROGRAMMER: Display this statement at the top of each page for Q4-Q13:** Based on the information presented on the website you saw, please answer the following questions. If you are not sure, please provide your best guess.]

**[INDICATION COMPREHENSION]**

Q4. DRUG X can help people with type 2 diabetes control their blood sugar.

True

False

Don’t know

**[SECONDARY CLAIM MISCONCPETIONS]**

Q5. DRUG X is for weight loss.

True

False

Don’t know

**[----------------------------------------New screen----------------------------------------]**

**[PERCEIVED BENEFIT – LIKELIHOOD]**

Q6. How likely is it that DRUG X would lower A1C levels for those with type 2 diabetes?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Not at all likely | 2 | 3 | 4 | 5 | 6  Extremely likely |

Q7. How likely is it that DRUG X would help with weight loss for those with type 2 diabetes?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Not at all likely | 2 | 3 | 4 | 5 | 6  Extremely likely |

**[----------------------------------------New screen----------------------------------------]**

**[PERCEIVED BENEFIT – MAGNITUDE]**

Q8. How much do you think DRUG X would lower A1C levels for patients with type 2 diabetes?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Would not lower it at all | 2 | 3 | 4 | 5 | 6  Would lower it substantially |

Q9. How much do you think DRUG X would help with weight loss for patients with type 2 diabetes?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Would not help at all | 2 | 3 | 4 | 5 | 6  Would help substantially |

**[----------------------------------------New screen----------------------------------------]**

**[PERCEIVED EFFICACY – COMPARATIVE GENERAL – MAIN INDICATION]**

Q10. DRUG X is more effective than other prescription drugs at lowering A1C level in people with type 2 diabetes.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly agree |

**[----------------------------------------New screen----------------------------------------]**

**[PERCEIVED EFFICACY – COMPARATIVE GENERAL – SECONDARY CLAIM]**

Q11. Patients with type 2 diabetes who use DRUG X will lose more weight than patients with type 2 diabetes who use other prescription drugs.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly agree |

**[----------------------------------------New screen----------------------------------------]**

[**PROGRAMMER: ASK Q12 and Q13 IF XCONDITION = 1, 2 OR 3 WHERE DRUG Y IS MENTIONED]**

**[PERCEIVED EFFICACY – COMPARATIVE MAIN INDICATION – DRUG Y]**

Q12. DRUG X is more effective than DRUG Y at lowering the A1C level in people with type 2 diabetes.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly agree |

**[----------------------------------------New screen----------------------------------------]**

**[PERCEIVED EFFICACY – COMPARATIVE SECONDARY CLAIM – DRUG Y]**

Q13. Patients with type 2 diabetes who use DRUG X will lose more weight than patients with type 2 diabetes who use DRUG Y.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly agree |

**[----------------------------------------New screen----------------------------------------]**

**[ATTITUDE TOWARD THE DRUG]**

Q14. Please rate how you feel about DRUG X. DRUG X is…

**[PROGRAMMER: RANDOMIZE ORDER OF ITEMS]**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | 1 | 2 | 3 | 4 | 5 | 6 |  |
| Q14\_1. A bad product | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | A good product |
| Q14\_2. Harmful | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Helpful |
| Q14\_3. Useless | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Useful |

**[----------------------------------------New screen----------------------------------------]**

**[BEHAVIORAL INTENTIONS]**

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’]**

Q15\_C. If I had to take a prescription drug to help with type 2 diabetes, I would consider taking DRUG X.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly  agree |

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP’]**

Q16\_P. If I had a patient with type 2 diabetes, I would consider prescribing DRUG X.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly  agree |

Q17. How likely are you to look for more information about DRUG X?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Not at all likely | 2 | 3 | 4 | 5 | 6  Extremely likely |

**[----------------------------------------New screen----------------------------------------]**

The website you saw had a statement that said:

“Assistance in lowering your A1C”

**[PRIMARY CLAIM COMPREHENSION]**

Q18. Imagine you wanted to explain to a [**PROGRAMMER: DISPLAY** friend or family member **IF COHORT = 1 ‘CONSUMERS’**/ **DISPLAY** patient **IF COHORT = 2 ‘HCP’**] what the statement above means. Using your own words, please explain the main idea of this statement.

[Open Field]

**[----------------------------------------New screen----------------------------------------]**

**[ATTITUDE TOWARD PRIMARY CLAIM]**

The website you saw had a statement that said:

“Assistance in lowering your A1C”

Q19. In my opinion, the statement is…

**[PROGRAMMER: RANDOMIZE ORDER OF ITEMS]**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | 1 | 2 | 3 | 4 | 5 | 6 |  |
| Q19\_1. Not prominent | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Prominent |
| Q19\_2. Unimportant | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Important |
| Q19\_3. Unclear | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Clear |

**[----------------------------------------New screen----------------------------------------]**

**[SECONDARY CLAIM COMPREHENSION]**

The website you saw had a statement that said:

“May provide additional benefit of weight loss”

Q20 Imagine you wanted to explain to a [**PROGRAMMER: DISPLAY** friend or family member **IF COHORT = 1 ‘CONSUMERS’**/ **DISPLAY** patient **IF COHORT = 2 ‘HCP’**] what the statement above means.

Using your own words, please explain the main idea of this statement.

.

[Open Field]

**[----------------------------------------New screen----------------------------------------]**

**[ATTITUDE TOWARD SECONDARY CLAIM]**

The website you saw had a statement that said:

“May provide additional benefit of weight loss”

Q21. In my opinion, the statement is…

**[PROGRAMMER: RANDOMIZE ORDER OF ITEMS]**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | 1 | 2 | 3 | 4 | 5 | 6 |  |
| Q21\_1. Not prominent | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Prominent |
| Q21\_2. Unimportant | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Important |
| Q21\_3. Unclear | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Clear |

**[----------------------------------------New screen----------------------------------------]**

**[COMPARATIVE CLAIM COMPREHENSION]**

**[PROGRAMMER: DISPLAY IF XCONDITION = 2 or 3]**

The website you saw had a statement that said:

“In a clinical trial, adults with an average starting weight of 197 pounds lost around 12 pounds on DRUG X compared to 4 pounds on DRUG Y.”

**[PROGRAMMER: DISPLAY IF XCONDITION = 1]**

The website you saw had a statement that said:

“In a clinical trial, adults with an average starting weight of 197 pounds lost more weight with DRUG X compared to DRUG Y.”

Q22. Imagine you wanted to explain to a [**PROGRAMMER: DISPLAY** friend or family member **IF COHORT = 1 ‘CONSUMERS’**/ **DISPLAY** patient **IF COHORT = 2 ‘HCP’**] what the statement above means.

Using your own words, please explain the main idea of this statement.

.

[Open Field]

**[----------------------------------------New screen----------------------------------------]**

**[ATTITUDE TOWARD COMPARATIVE CLAIM]**

**[PROGRAMMER: DISPLAY IF XCONDITION = 2 or 3]**

The website you saw had a statement that said:

“In a clinical trial, adults with an average starting weight of 197 pounds lost around 12 pounds on DRUG X compared to 4 pounds on DRUG Y.”

**[PROGRAMMER: DISPLAY IF XCONDITION = 1]**

The website you saw had a statement that said:

“In a clinical trial, adults with an average starting weight of 197 pounds lost more weight with DRUG X compared to DRUG Y.”

Q23. In my opinion, the statement is…

**[PROGRAMMER: RANDOMIZE ORDER OF ITEMS]**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | 1 | 2 | 3 | 4 | 5 | 6 |  |
| Q23\_1. Not prominent | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Prominent |
| Q23\_2. Unimportant | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Important |
| Q23\_3. Unclear | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Clear |

**[----------------------------------------New screen----------------------------------------]**

**[DISCLOSURE COMPREHENSION]**

**[PROGRAMMER: DISPLAY IF XCONDITION = 1, 3, 4 or 6]**

The website you saw had a statement that said:

“Even though DRUG X is not made for weight loss, it could also help some people lose some weight.”

**[PROGRAMMER: DISPLAY IF XCONDITION = 2 or 5]**

The website you saw had a statement that said:

“DRUG X could help some people lose some weight.”

Q24. Imagine you wanted to explain to a [**PROGRAMMER: DISPLAY** friend or family member **IF COHORT = 1 ‘CONSUMERS’**/ **DISPLAY** patient **IF COHORT = 2 ‘HCP’**] what the statement above means.

Using your own words, please explain the main idea of this statement.

.

[Open Field]

**[ATTITUDE TOWARD THE DISCLOSURE]**

‘

**[PROGRAMMER: DISPLAY IF XCONDITION = 1, 3, 4 or 6]**

The website you saw had a statement that said:

“Even though DRUG X is not made for weight loss, it could also help some people lose some weight.”

**[PROGRAMMER: DISPLAY IF XCONDITION = 2 or 5]**

The website you saw had a statement that said:

“DRUG X could help some people lose some weight.”

Q25. In my opinion, the statement is…

**[PROGRAMMER: RANDOMIZE ORDER OF ITEMS]**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | 1 | 2 | 3 | 4 | 5 | 6 |  |
| Q25\_1. Not prominent | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Prominent |
| Q25\_2. Unimportant | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Important |
| Q25\_3. Unclear | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Clear |

**[PROGRAMMER: DISPLAY IF XCONDITION = 1,2,3,4,5,6]**

The website you saw had a statement that said:

“DRUG X could help some people lose some weight.”

**[ATTRIBUTION]**

Q26. Drug manufacturers are required by law to provide statements similar to the one you just read.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly agree |

**[----------------------------------------New screen----------------------------------------]**

**[PERCEIVED RISK – LIKELIHOOD]**

Q27. How likely is it that [**PROGRAMMER: DISPLAY** people with type 2 diabetes would experience at least one side effect if they took DRUG X **IF COHORT = 1 ‘CONSUMERS’**/ **DISPLAY** patients with type 2 diabetes would experience at least one side effect if they took DRUG X? **IF COHORT = 2 ‘HCP’**]

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Not at all likely | 2 | 3 | 4 | 5 | 6  Extremely likely |

**[PERCEIVED RISK – SEVERITY]**

Q28. How serious are DRUG X’s side effects?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Not at all serious | 2 | 3 | 4 | 5 | 6  Extremely serious |

**[----------------------------------------New screen----------------------------------------]**

**[PERCEIVED RISK – COMPARATIVE GENERAL]**

Q29. DRUG X is safer than other prescription drugs that lower A1C level.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly  agree |

**[----------------------------------------New screen----------------------------------------]**

**[PROGRAMMER: DISPLAY IF XCONDITION = 1, 2 OR 3]**

**[PERCEIVED RISK – COMPARATIVE MAIN INDICATION – DRUG Y]**

Q30. DRUG X is safer than DRUG Y at lowering the A1C level.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly  agree |

**[----------------------------------------New screen----------------------------------------]**

**[TRUST IN ADVERTISING]**

Q31. How much do you trust information provided by pharmaceutical companies about prescription drugs?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Not at all | 2 | 3 | 4 | 5 | 6  A lot |

**[HEALTH LITERACY]**

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’]**

Q32\_C. How often do you need to have someone help you when you read instructions, pamphlets, or other written material from your doctor or pharmacy?

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 1  Never | 2  Rarely | 3  Sometimes | 4  Often | 5  Always |

**[----------------------------------------New screen----------------------------------------]**

**[PAST EXPERIENCE WITH DISEASE]**

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’]**

Q33\_C. Have you ever been diagnosed with diabetes?

1. Yes
2. No

Don’t know

**[----------------------------------------New screen----------------------------------------]**

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’ AND Q33\_C = 1 ‘YES’]**

Q34\_C. Have you ever taken a prescription drug for diabetes?

1. Yes, I am currently taking
2. Yes, I have in the past, but I am not currently taking
3. No, I have never taken

Don’t know

**[----------------------------------------New screen----------------------------------------]**

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’]**

Q35\_C. Have you ever taken a prescription drug for weight loss?

1. Yes, I am currently taking
2. Yes, I have in the past, but I am not currently taking
3. No, I have never taken
4. Don’t know

**[# OF PRESCRIPTIONS/WEEK]**

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP’]**

Q36\_P. In a normal week, about how many prescriptions do you write? This includes both refills and new prescriptions. If you are not sure, please provide your best guess.

\_\_\_\_\_ prescriptions in a normal week

[**YEARS IN PRACTICE**]

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP’]**

Q37\_P. Since completing your residency, how many years have you been a health care provider?

\_\_\_\_\_ years

**[----------------------------------------New screen----------------------------------------]**

**PRETEST FOLLOW-UP**

Q38. On a scale from 1-5, where 1 is completely negative and 5 is completely positive, how would you rate your experience with taking this survey?

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 1  Completely Negative | 2 | 3 | 4 | 5  Completely positive |

Q39. Please tell us the main reasons for your rating score above.

[Open Field]

**DEBRIEF**

The purpose of this study is to learn about reactions to prescription drug information. [PROGRAMMER: IF XCONDITION = 1, 2, OR 3 DISPLAY “DRUG X is not a real product and is not available for sale”; IF XCONDITION = 1, 2, OR 3 DISPLAY “DRUG X and DRUG Y are not real products and are not available for sale”]. To get a real-life reaction, [PROGRAMMER: IF XCONDITION = 1, 2, OR 3 DISPLAY “we used a pretend product in this study”; IF XCONDITION = 1, 2, OR 3 DISPLAY “we used pretend products in this study”]. [PROGRAMMER: IF COHORT = 1 “CONSUMERS” DISPLAY Please see your health care professional for questions about type 2 diabetes or weight loss.

You have been very helpful. Thank you very much for your participation!

**FDA Secondary and Comparative Claims and Biosimilars Disclosure Study**

**Study 2, Biosimilars Survey**

**[Intro screen 1 - Website]**

[**DISPLAY]**

You are eligible to participate in the study.

On the next screen, we will ask you to look at an ad for a new prescription drug to treat rheumatoid arthritis. Some parts of the ad have been blurred out; just focus on what you can see.

Drug names have been changed for the purpose of this survey.

Also, assume that any drugs mentioned in this study have been approved by FDA.

**[----------------------------------------New screen----------------------------------------]**

A few tips when taking this survey:

Please make sure you are comfortable and can read the screen from where you sit.

**Take as much time as you need reading the information in the ad.** Once you advance past the ad to the survey questions, you will not be able to return to it.

**[PROGRAMMER: Display website correspondent to the participant’s experimental condition:**

**IF COHORT = 1 ‘Consumer’ AND XCONDITION = 1 ‘No Disclosure’, DISPLAY IMAGE: S2\_Cons\_1.jpg**

**IF COHORT = 1 ‘Consumer’ AND XCONDITION = 2 ‘Disclosure 1’, DISPLAY IMAGE: S2\_Cons\_2.jpg**

**IF COHORT = 1 ‘Consumer’ AND XCONDITION = 3 ‘Disclosure 2’, DISPLAY IMAGE: S2\_Cons\_3.jpg**

**IF COHORT = 1 ‘Consumer’ AND XCONDITION = 4 ‘Disclosure 3’, DISPLAY IMAGE: S2\_Cons\_4.jpg**

**IF COHORT = 1 ‘Consumer’ AND XCONDITION = 5 ‘Disclosure 4’, DISPLAY IMAGE: S2\_Cons\_5.jpg**

**IF COHORT = 1 ‘Consumer’ AND XCONDITION = 6 ‘Disclosure 5’, DISPLAY IMAGE: S2\_Cons\_6.jpg**

**IF COHORT = 1 ‘Consumer’ AND XCONDITION = 7 ‘Disclosure 6’, DISPLAY IMAGE: S2\_Cons\_7.jpg**

**IF COHORT = 1 ‘Consumer’ AND XCONDITION = 8 ‘Disclosure 7’, DISPLAY IMAGE: S2\_Cons\_8.jpg**

**IF COHORT = 1 ‘HCP’ AND XCONDITION = 1 ‘No Disclosure, DISPLAY IMAGE: S2\_HCP\_1.jpg**

**IF COHORT = 1 ‘HCP’ AND XCONDITION = 2 ‘Disclosure 1’, DISPLAY IMAGE: S2\_HCP \_2. jpg**

**IF COHORT = 1 ‘HCP’ AND XCONDITION = 3 ‘Disclosure 2’, DISPLAY IMAGE: S2\_HCP\_3. jpg**

**IF COHORT = 1 ‘HCP’ AND XCONDITION = 4 ‘Disclosure 3’, DISPLAY IMAGE: S2\_HCP\_4.jpg**

**IF COHORT = 1 ‘HCP’ AND XCONDITION = 5 ‘Disclosure 4’, DISPLAY IMAGE: S2\_HCP\_5. jpg**

**IF COHORT = 1 ‘HCP’ AND XCONDITION = 6 ‘Disclosure 5’, DISPLAY IMAGE: S2\_HCP\_6. jpg**

**IF COHORT = 1 ‘HCP’ AND XCONDITION = 7 ‘Disclosure 6’, DISPLAY IMAGE: S2\_HCP\_7. jpg**

**IF COHORT = 1 ‘HCP’ AND XCONDITION = 8 ‘Disclosure 7’, DISPLAY IMAGE: S2\_HCP\_8. jpg**

**[Please disable the “Next” button for 5 seconds]**

*Please click the ‘Next’ button to continue. Once you leave this screen you will not be able to return to it.*

**[----------------------------------------New screen----------------------------------------]**

**[Show Ad]**

**[----------------------------------------New screen----------------------------------------]**

**[SINGLE PUNCH]**

Q1. Were you able to view the ad?

1 Yes

2 No **[TERMINATE; DISPLAY ‘Thank and Terminate’]**

**[----------------------------------------New screen----------------------------------------]**

[**Intro screen 2 - Survey]**

[**PROGRAMMER:** For remaining questions, if respondent does not provide response, prompt with, “Are you sure you don’t want to provide a response?” before allowing to continue.]

Now please answer the following questions **based on the information you saw in the ad.**

**[----------------------------------------New screen----------------------------------------]**

**[PROGRAMMER: DISPLAY IF XCONDITION = 2, 3, 4, 5, 6, 7, 8]**

**[DISCLOSURE COMPREHENSION]**

Q2. Imagine you wanted to explain to [**PROGRAMMER: IF COHORT = 1 “CONSUMERS” DISPLAY** a friend or family member **/ IF COHORT = 2 “HCP” DISPLAY** a patient] what the ad you just saw means. Using your own words, please explain the main idea of the ad.

[Open Field]

**[----------------------------------------New screen----------------------------------------]**

**[PROGRAMMER: Display this statement at the top of each page for Q3-Q12:** Based on the information presented in the ad you saw, please answer the following questions. **If you are not sure, please provide your best guess.**]

**[PROGRAMMER: DISPLAY IF XCONDITION = 2, 3, 4, 5, 6, 7 OR 8]**

**[ATTITUDE TOWARD DISCLOSURE]**

Q3. Please tell us your opinion about the information you saw in the ad. In my opinion, the information was…

**[PROGRAMMER: RANDOMIZE ORDER OF ITEMS]**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | 1 | 2 | 3 | 4 | 5 | 6 |  |
| Q3\_1. Too brief | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Too long |
| Q3\_2. Unimportant | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Important |
| Q3\_3. Unclear | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Clear |

**[PROGRAMMER: DISPLAY IF XCONDITION = 2, 3, 4, 5, 6, 7 OR 8]**

**[ATTRIBUTION]**

Q4. Drug manufacturers are required by law to provide statements similar to those you just read in the ad.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly agree |

**[PROGRAMMER: RANDOMIZE THE ORDER OF Q5/Q6 AND Q7/Q8 SUCH THAT ONE TIME Q5/Q6 ARE PRESENTED FIRST AND THEN NEXT TIME Q7/Q8 ARE PRESENTED FIRST]**

**[PERCEIVED RISK – SEVERITY]**

Q5. How serious are DRUG Z’s side effects?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Not at all serious | 2 | 3 | 4 | 5 | 6  Extremely serious |

**[PERCEIVED RISK – LIKELIHOOD]**

Q6. How likely is it that [people with rheumatoid arthritis/patients with rheumatoid arthritis] would experience at least one side effect if [/they] took DRUG Z?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Not at all likely | 2 | 3 | 4 | 5 | 6  Extremely likely |

**[----------------------------------------New screen----------------------------------------]**

**[PERCEIVED BENEFIT – MAGNITUDE]**

Q7. How much would DRUG Z improve rheumatoid arthritis symptoms?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  No improvement | 2 | 3 | 4 | 5 | 6  Substantial improvement |

**[PERCEIVED BENEFIT – LIKELIHOOD]**

Q8. How likely is it that DRUG Z would improve rheumatoid arthritis symptoms?

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| 1  Not at all likely | 2 | 3 | 4 | 5 |  | 6  Extremely likely |

**[----------------------------------------New screen----------------------------------------]**

**[PERCEIVED RISK – COMPARATIVE]**

Q9. DRUG Z is safer than other prescription drugs that treat the same medical condition.

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree |  | 2 | 3 | 4 | 5 | 6  Strongly agree |

**[PERCEIVED EFFICACY – COMPARATIVE]**

Q10. DRUG Z is more effective than other prescription drugs that treat the same medical condition.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly agree |

**[----------------------------------------New screen----------------------------------------]**

**[PROGRAMMER: DISPLAY IF XCONDITION = 4, 6, 8]**

**[PERCEIVED RISK – COMPARATIVE]**

Q11. DRUG Z is safer than DRUG Q.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly agree |

**[PROGRAMMER: DISPLAY IF XCONDITION = 4, 6, 8]**

**[PERCEIVED EFFICACY – COMPARATIVE]**

Q12. DRUG Z is more effective than DRUG Q.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly agree |

**[----------------------------------------New screen----------------------------------------]**

**[PROGRAMMER: DISPLAY Q12 IF COHORT = 2 “HCP” AND XCONDITION = 3, 4, 5, 6, 7 OR 8]**

**[DRUG INTERCHANGEABILITY]**

Q13\_P. DRUG Z and **[PROGRAMMER: IF XCONDITION = 3, 5 OR 7 DISPLAY** thereference medication/ **IF XCONDITION = 4, 6 OR 8 DISPLAY** DRUG Q**]** can be used interchangeably.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly agree |

**[----------------------------------------New screen----------------------------------------]**

**[ATTTIUDE TOWARD THE DRUG]**

Q14. Please rate how you feel about DRUG Z. DRUG Z is…

**[PROGRAMMER: RANDOMIZE ORDER OF ITEMS]**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | 1 | 2 | 3 | 4 | 5 | 6 |  |
| Q14\_1. A bad product | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | A good product |
| Q14\_2. Harmful | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Helpful |
| Q14\_3. Useless | ❒ | ❒ | ❒ | ❒ | ❒ | ❒ | Useful |

**[----------------------------------------New screen----------------------------------------]**

**[BEHAVIORAL INTENTIONS]**

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’]**

Q15\_C. If I had to take a prescription drug to help with rheumatoid arthritis, I would consider taking DRUG Z.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly  agree |

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP’]**

Q16\_P. If I had a patient newly diagnosed with rheumatoid arthritis, I would consider prescribing DRUG Z.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly  agree |

Q17. How likely are you to look for more information about DRUG Z?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Not at all likely | 2 | 3 | 4 | 5 | 6  Extremely likely |

**[PROGRAMMER: DISPLAY Q12 IF COHORT = 1 ‘CONSUMERS’**

Q18\_C. If I were taking another prescription drug for rheumatoid arthritis, I would ask my doctor to switch my prescription to DRUG Z?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Strongly disagree | 2 | 3 | 4 | 5 | 6  Strongly  agree |

**[----------------------------------------New screen----------------------------------------]**

**[PROGRAMMER: Display this statement at the top of each page for Q19-Q21:** Based on the information presented in the ad you saw, please answer the following questions. **If you are not sure, please provide your best guess**.]

**[DISCLOSURE COMPREHENSION #1]**

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS and XCONDITION=3-8’]**

Q19\_C. Which of the following choices best summarizes what the statement displayed below means?

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’ and XCONDITION = 3, 5 OR 7]**

“This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.”

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’ and XCONDITION = 4, 6 OR 8]**

“This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.”

**[PROGRAMMER: RANDOMIZE ORDER OF RESPONSE OPTIONS]**

1 **[CORRECT]** DRUG Z is as effective and as safe as the original biologic.

2 **[FOIL]** DRUG Z is more effective and safer than the original biologic.

3 **[FOIL]** DRUG Z is less effective and less safe than the original biologic.

4 **[FOIL]** It is not known if DRUG Z is as effective and as safe as the original biologic.

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP’ AND XCONDITION=3-8]**

Q19\_P. Which of the following choices best summarizes what the statement displayed below means?

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP’ and XCONDITION = 3, 5 OR 7]**

**“**This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.”

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP’ and XCONDITION = 4, 6 OR 8]**

“This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.”

**[PROGRAMMER: RANDOMIZE ORDER OF RESPONSE OPTIONS]**

1 **[CORRECT]** DRUG Z and the reference product are similar in terms of their safety and efficacy profiles.

2 **[FOIL]** DRUG Z is more effective and safer than the reference product.

3 **[FOIL]** DRUG Z is less effective and less safe than the reference product.

4 **[FOIL]** It is not known if DRUG Z is as effective and as safe as the reference product.

**[----------------------------------------New screen----------------------------------------]**

**[DISCLOSURE COMPREHENSION #2]**

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’ AND XCONDITION=5-8]**

Q20\_C. Which of the following choices best summarizes what the statement displayed below means?

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’ and XCONDITION = 5 OR 7]**

“Biosimilars are made from the same types of sources as the FDA-approved original biologic.”

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’ and XCONDITION = 6 OR 8]**

“This biosimilar is made from the same types of sources as DRUG Q.”

**[PROGRAMMER: RANDOMIZE ORDER OF RESPONSE OPTIONS]**

1 **[CORRECT]** DRUG Z is made in a way such that its composition is highly similar to those of **[PROGRAMMER: IF XCONDITION = 5 OR 7 DISPLAY** the original biologic**, IF XCONDITION = 6 OR 8 DISPLAY** DRUG Q**]**.

2 **[FOIL]** DRUG Z is made in the same laboratory as **[PROGRAMMER: IF XCONDITION = 5 OR 7 DISPLAY** the original biologic**, IF XCONDITION = 6 OR 8 DISPLAY** DRUG Q**]**.

.

3 **[FOIL]** DRUG Z is an exact replica of **[PROGRAMMER: IF XCONDITION = 5 OR 7 DISPLAY** the original biologic**, IF XCONDITION = 6 OR 8 DISPLAY** DRUG Q**]**, but has a different name.

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP’ AND XCONDITION=5-8]**

Q20\_P. Which of the following choices best summarizes what the statement displayed below means?

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP’ and XCONDITION = 5 OR 7]**

“Biosimilars are made from the same types of sources as the FDA-approved reference product.”

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP’ and XCONDITION = 6 OR 8]**

“This biosimilar is made from the same types of sources as DRUG Q.”

**[PROGRAMMER: RANDOMIZE ORDER OF RESPONSE OPTIONS]**

1 **[CORRECT]** DRUG Z is made in a way such that its composition is highly similar to those of the **[PROGRAMMER: IF XCONDITION = 5 OR 7 DISPLAY** the reference product**, IF XCONDITION = 6 OR 8** DRUG Q**]**.

2 **[FOIL]** DRUG Z is made in the same laboratory as the **[PROGRAMMER: IF XCONDITION = 5 OR 7 DISPLAY** the reference product**, IF XCONDITION = 6 OR 8** DRUG Q**]**.

3 **[FOIL]** DRUG Z is the same product as **[PROGRAMMER: IF XCONDITION = 5 OR 7 DISPLAY** the reference product**, IF XCONDITION = 6 OR 8** DRUG Q**]**, but has a different name.

**[----------------------------------------New screen----------------------------------------]**

**[DISCLOSURE COMPREHENSION #3]**

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’ AND XCONDITION =7,8]**

Q21\_C.

If DRUG Z is a 40mg/0.8 ml injection, which of the following is true based on the statement below?

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’ and XCONDITION = 7]**

DRUG Z is given the same way and has the same strength and dosage as the FDA-approved original biologic.

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’ and XCONDITION = 8]**

DRUG Z is given the same way and has the same strength and dosage as DRUG Q.

**[PROGRAMMER: RANDOMIZE ORDER OF RESPONSE OPTIONS]**

1 **[CORRECT]** **[PROGRAMMER: IF XCONDITION = 7 DISPLAY** the original biologic**, IF XCONDITION = 8 DISPLAY** DRUG Q**]** is taken as an injection.

2 **[FOIL]** **[PROGRAMMER: IF XCONDITION = 7 DISPLAY** the original biologic**, IF XCONDITION = 8 DISPLAY** DRUG Q**]** is taken as a pill while DRUG Z is taken as an injection.

3 **[FOIL]** **[PROGRAMMER: IF XCONDITION = 7 DISPLAY** the original biologic**, IF XCONDITION = 8 DISPLAY** DRUG Q**]** is twice the dosage of DRUG Z.

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP and XCONDITION=7,8]**

Q21\_P. If DRUG Z is a 40mg/0.8 ml injection, which of the following is true based on the statement below?

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP’ and XCONDITION = 7]**

DRUG Z has the same route of administration, dosage form, and strength as an existing FDA-approved reference product.

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP’ and XCONDITION = 8]**

DRUG Z has the same route of administration, dosage form, and strength as DRUG Q.

1 **[CORRECT]** **[PROGRAMMER: IF XCONDITION = 7 DISPLAY** the reference product**, IF XCONDITION = 8** **DISPLAY** DRUG Q**]** is taken as an injection.

2 **[FOIL]** **[PROGRAMMER: IF XCONDITION = 7 DISPLAY** the reference product**, IF XCONDITION = 8** **DISPLAY** DRUG Q**]** is taken as a pill while DRUG Z is taken as an injection.

3 **[FOIL]** **[PROGRAMMER: IF XCONDITION = 7 DISPLAY** the reference product**, IF XCONDITION = 8** **DISPLAY** DRUG Q**]** is twice the dosage of DRUG Z.

**[----------------------------------------New screen----------------------------------------]**

**[DISCLOSURE PREFERENCE #1]**

For the next few items, we will show you two different descriptions for DRUG Z. While some of the descriptions will be very similar to each other, each pair will differ in some way. After carefully reading each pair of descriptions, please choose the one you prefer.

Assume that all medications named in the following descriptions have been approved by FDA.

**[PROGRAMMER: WE PRESENT HERE A SAMPLE FORMAT FOR THE FOLLOWING SERIES OF ITEMS. NOTE: (1) HEADERS SHOULD READ “OPTION A” ON LEFT AND “OPTION B” ON RIGHT; (2) DO NOT SHOW THE HEADERS BELOW HIGHLIGHTED IN YELLOW, LANGUAGE IS FOR INTERNAL PURPOSES ONLY; (3) TEXT THAT APPEARS UNDER OPTION A OR OPTION B WILL BE RANDOMIZED; (4) WIDTH OF THE COLUMNS SHOULD BE IDENTICAL; (5) PLEASE ALSO NOTE THE COLOR CODING OF TEXT WHERE PURPLE IS INTENDED TO INDICATE ALTERNATIVE TEXT AND BLUE INDICATES NEW TEXT; (6) PLEASE ALSO NOTE THAT THE TEXT ‘CHUNKS’ SHOULD ALIGN]**

**[PROGRAMMER: RANDOMIZE THE TEXT BLOCK THAT IS ASSIGNED TO “OPTION A” AND “OPTION B”]**

|  |  |
| --- | --- |
| **Option A** | **Option B** |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. |

**[PROGRAMMER: KEEP “NO PREFERENCE” LAST. REPEAT THIS QUESTION AFTER EACH PRESENTATION; ONE PER SCREEN]**

Q22\_P. Which do you **prefer**?

Option A

Option B

No preference

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 2; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 2 Text (assigned) | Condition 3 Text (comparator) |
| DRUG Z is a biosimilar. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 3; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 3 Text (assigned) | Condition 2 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. | DRUG Z is a biosimilar. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 4; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 4 Text (assigned) | Condition 2 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product. | DRUG Z is a biosimilar. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 5; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 5 Text (assigned) | Condition 2 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product. | DRUG Z is a biosimilar. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 6; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 6 Text (assigned) | Condition 2 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q. | DRUG Z is a biosimilar. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 7; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 7 Text (assigned) | Condition 2 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product.  DRUG Z has the same route of administration, dosage form, and strength as an existing FDA-approved reference product. | DRUG Z is a biosimilar. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 8; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 8 Text (assigned) | Condition 2 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z has the same route of administration, dosage form, and strength as DRUG Q. | DRUG Z is a biosimilar. |

**[----------------------------------------New screen----------------------------------------]**

**[DISCLOSURE PREFERENCE #2]**

**[PROGRAMMER: RANDOMIZE THE TEXT BLOCK THAT IS ASSIGNED TO “OPTION A” AND “OPTION B”]**

|  |  |
| --- | --- |
| **OPTION A** | **OPTION B** |
| **SHOW TEXT FOR OPTION A** | **SHOW TEXT FOR OPTION B** |

**[PROGRAMMER: KEEP “NO PREFERENCE” LAST]**

Q23\_P. Which do you **prefer**?

Option A

Option B

No preference

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 2; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 2 Text (assigned) | Condition 4 Text (comparator) |
| DRUG Z is a biosimilar. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 3; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 3 Text (assigned) | Condition 4 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 4; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 4 Text (assigned) | Condition 3 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 5; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 5 Text (assigned) | Condition 3 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 6; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 6 Text (assigned) | Condition 3 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 7; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 7 Text (assigned) | Condition 3 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product.  DRUG Z has the same route of administration, dosage form, and strength as an existing FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 8; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 8 Text (assigned) | Condition 3 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z has the same route of administration, dosage form, and strength as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. |

**[----------------------------------------New screen----------------------------------------]**

**[DISCLOSURE PREFERENCE #3]**

**[PROGRAMMER: RANDOMIZE THE TEXT BLOCK THAT IS ASSIGNED TO “OPTION A” AND “OPTION B”]**

|  |  |
| --- | --- |
| **OPTION A** | **OPTION B** |
| **SHOW TEXT FOR OPTION A** | **SHOW TEXT FOR OPTION B** |

**[PROGRAMMER: KEEP “NO PREFERENCE” LAST]**

Q24\_P. Which do you **prefer**?

Option A

Option B

No preference

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 2; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 2 Text (assigned) | Condition 5 Text (comparator) |
| DRUG Z is a biosimilar. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 3; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 3 Text (assigned) | Condition 5 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 4; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 4 Text (assigned) | Condition 5 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 5; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 5 Text (assigned) | Condition 4 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 6; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 6 Text (assigned) | Condition 4 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 7; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 7 Text (assigned) | Condition 4 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product.  DRUG Z has the same route of administration, dosage form, and strength as an existing FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 8; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 8 Text (assigned) | Condition 4 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z has the same route of administration, dosage form, and strength as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product. |

**[----------------------------------------New screen----------------------------------------]**

**[DISCLOSURE PREFERENCE #4]**

**[PROGRAMMER: RANDOMIZE THE TEXT BLOCK THAT IS ASSIGNED TO “OPTION A” AND “OPTION B”]**

|  |  |
| --- | --- |
| **OPTION A** | **OPTION B** |
| **SHOW TEXT FOR OPTION A** | **SHOW TEXT FOR OPTION B** |

**[PROGRAMMER: KEEP “NO PREFERENCE” LAST]**

Q25\_P. Which do you **prefer**?

Option A

Option B

No preference

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 2; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 2 Text (assigned) | Condition 6 Text (comparator) |
| DRUG Z is a biosimilar. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 3; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 3 Text (assigned) | Condition 6 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 4; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 4 Text (assigned) | Condition 6 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 5; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 5 Text (assigned) | Condition 6 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 6; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 6 Text (assigned) | Condition 5 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 7; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 7 Text (assigned) | Condition 5 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product.  DRUG Z has the same route of administration, dosage form, and strength as an existing FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 8; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 8 Text (assigned) | Condition 5 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z has the same route of administration, dosage form, and strength as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product. |

**[----------------------------------------New screen----------------------------------------]**

**[DISCLOSURE PREFERENCE #5]**

**[PROGRAMMER: RANDOMIZE THE TEXT BLOCK THAT IS ASSIGNED TO “OPTION A” AND “OPTION B”]**

|  |  |
| --- | --- |
| **OPTION A** | **OPTION B** |
| **SHOW TEXT FOR OPTION A** | **SHOW TEXT FOR OPTION B** |

**[PROGRAMMER: KEEP “NO PREFERENCE” LAST]**

Q26\_P. Which do you **prefer**?

Option A

Option B

No preference

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 2; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 2 Text (assigned) | Condition 7 Text (comparator) |
| DRUG Z is a biosimilar. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product.  DRUG Z has the same route of administration, dosage form, and strength as an existing FDA-approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 3; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 3 Text (assigned) | Condition 7 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product.  DRUG Z has the same route of administration, dosage form, and strength as an existing FDA -approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 4; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 4 Text (assigned) | Condition 7 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product.  DRUG Z has the same route of administration, dosage form, and strength as an existing FDA -approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 5; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 5 Text (assigned) | Condition 7 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product.  DRUG Z has the same route of administration, dosage form, and strength as an existing FDA -approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 6; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 6 Text (assigned) | Condition 7 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product.  DRUG Z has the same route of administration, dosage form, and strength as an existing FDA -approved reference product. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 7; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 7 Text (assigned) | Condition 6 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product.  DRUG Z has the same route of administration, dosage form, and strength as an existing FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 8; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 8 Text (assigned) | Condition 6 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z has the same route of administration, dosage form, and strength as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q. |

**[----------------------------------------New screen----------------------------------------]**

**[DISCLOSURE PREFERENCE #6]**

**[PROGRAMMER: RANDOMIZE THE TEXT BLOCK THAT IS ASSIGNED TO “OPTION A” AND “OPTION B”]**

|  |  |
| --- | --- |
| **OPTION A** | **OPTION B** |
| **SHOW TEXT FOR OPTION A** | **SHOW TEXT FOR OPTION B** |

**[PROGRAMMER: KEEP “NO PREFERENCE” LAST]**

Q27\_P. Which do you **prefer**?

Option A

Option B

No preference

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 2; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 2 Text (assigned) | Condition 8 Text (comparator) |
| DRUG Z is a biosimilar. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z has the same route of administration, dosage form, and strength as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 3; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 3 Text (assigned) | Condition 7 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z has the same route of administration, dosage form, and strength as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 4; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 4 Text (assigned) | Condition 8 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z has the same route of administration, dosage form, and strength as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 5; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 5 Text (assigned) | Condition 8 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z has the same route of administration, dosage form, and strength as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 6; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 6 Text (assigned) | Condition 8 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z has the same route of administration, dosage form, and strength as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 7; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 7 Text (assigned) | Condition 8 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product.  DRUG Z has the same route of administration, dosage form, and strength as an existing FDA-approved reference product. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z has the same route of administration, dosage form, and strength as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 2 “HCP” AND XCONDITION = 8; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 8 Text (assigned) | Condition 7 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from DRUG Q, an existing FDA-approved reference product.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z has the same route of administration, dosage form, and strength as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an existing FDA-approved reference product.  Biosimilars are made from the same types of sources as the FDA-approved reference product.  DRUG Z has the same route of administration, dosage form, and strength as an existing FDA-approved reference product. |

**[----------------------------------------New screen----------------------------------------]**

**[DISCLOSURE PREFERENCE #1]**

**[PROGRAMMER: RANDOMIZE THE TEXT BLOCK THAT IS ASSIGNED TO “OPTION A” AND “OPTION B”]**

For the next few items, we will show you two different descriptions for DRUG Z. While some of the descriptions will be very similar to each other, each pair will differ in some way. After reading each pair of descriptions, please choose the one you prefer.

|  |  |
| --- | --- |
| **OPTION A** | **OPTION B** |
| **SHOW TEXT FOR OPTION A** | **SHOW TEXT FOR OPTION B** |

**[PROGRAMMER: KEEP “NO PREFERENCE” LAST]**

Q28\_C. Which do you **prefer**?

Option A

Option B

No preference

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 2; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 2 Text (assigned) | Condition 3 Text (comparator) |
| DRUG Z is a biosimilar. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 3; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 3 Text (assigned) | Condition 2 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic. | DRUG Z is a biosimilar. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 4; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 4 Text (assigned) | Condition 2 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic. | DRUG Z is a biosimilar. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 5; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 5 Text (assigned) | Condition 2 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic. | DRUG Z is a biosimilar. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 6; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 6 Text (assigned) | Condition 2 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q. | DRUG Z is a biosimilar. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 7; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 7 Text (assigned) | Condition 2 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic.  DRUG Z is given the same way and has the same strength and dosage as the FDA-approved original biologic. | DRUG Z is a biosimilar. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 8; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 8 Text (assigned) | Condition 2 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z is given the same way and has the same strength and dosage as DRUG Q. | DRUG Z is a biosimilar. |

**[----------------------------------------New screen----------------------------------------]**

**[DISCLOSURE PREFERENCE #2]**

**[PROGRAMMER: RANDOMIZE THE TEXT BLOCK THAT IS ASSIGNED TO “OPTION A” AND “OPTION B”]**

|  |  |
| --- | --- |
| **OPTION A** | **OPTION B** |
| **SHOW TEXT FOR OPTION A** | **SHOW TEXT FOR OPTION B** |

**[PROGRAMMER: KEEP “NO PREFERENCE” LAST]**

Q29\_C. Which do you **prefer**?

Option A

Option B

No preference

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 2; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 2 Text (assigned) | Condition 4 Text (comparator) |
| DRUG Z is a biosimilar. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 3; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 3 Text (assigned) | Condition 4 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 4; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 4 Text (assigned) | Condition 3 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 5; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 5 Text (assigned) | Condition 3 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 6; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 6 Text (assigned) | Condition 3 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 7; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 7 Text (assigned) | Condition 3 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic.  DRUG Z is given the same way and has the same strength and dosage as the FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 8; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 8 Text (assigned) | Condition 3 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z is given the same way and has the same strength and dosage as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic. |

**[----------------------------------------New screen----------------------------------------]**

**[DISCLOSURE PREFERENCE #3]**

**[PROGRAMMER: RANDOMIZE THE TEXT BLOCK THAT IS ASSIGNED TO “OPTION A” AND “OPTION B”]**

|  |  |
| --- | --- |
| **OPTION A** | **OPTION B** |
| **SHOW TEXT FOR OPTION A** | **SHOW TEXT FOR OPTION B** |

**[PROGRAMMER: KEEP “NO PREFERENCE” LAST]**

Q30\_C Which do you **prefer**?

Option A

Option B

No preference

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 2; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 2 Text (assigned) | Condition 5 Text (comparator) |
| DRUG Z is a biosimilar. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 3; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 3 Text (assigned) | Condition 5 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 4; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 4 Text (assigned) | Condition 5 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 5; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 5 Text (assigned) | Condition 4 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 6; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 6 Text (assigned) | Condition 4 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 7; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 7 Text (assigned) | Condition 4 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic.  DRUG Z is given the same way and has the same strength and dosage as the FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 8; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 8 Text (assigned) | Condition 4 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z is given the same way and has the same strength and dosage as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic. |

**[----------------------------------------New screen----------------------------------------]**

**[DISCLOSURE PREFERENCE #4]**

**[PROGRAMMER: RANDOMIZE THE TEXT BLOCK THAT IS ASSIGNED TO “OPTION A” AND “OPTION B”]**

|  |  |
| --- | --- |
| **OPTION A** | **OPTION B** |
| **SHOW TEXT FOR OPTION A** | **SHOW TEXT FOR OPTION B** |

**[PROGRAMMER: KEEP “NO PREFERENCE” LAST]**

Q31\_C. Which do you **prefer**?

Option A

Option B

No preference

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 2; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 2 Text (assigned) | Condition 6 Text (comparator) |
| DRUG Z is a biosimilar. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 3; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 3 Text (assigned) | Condition 6 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 4; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 4 Text (assigned) | Condition 6 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 5; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 5 Text (assigned) | Condition 6 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 6; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 6 Text (assigned) | Condition 5 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 7; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 7 Text (assigned) | Condition 5 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic.  DRUG Z is given the same way and has the same strength and dosage as the FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 8; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 8 Text (assigned) | Condition 5 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z is given the same way and has the same strength and dosage as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic. |

**[----------------------------------------New screen----------------------------------------]**

**[DISCLOSURE PREFERENCE #5]**

**[PROGRAMMER: RANDOMIZE THE TEXT BLOCK THAT IS ASSIGNED TO “OPTION A” AND “OPTION B”]**

|  |  |
| --- | --- |
| **OPTION A** | **OPTION B** |
| **SHOW TEXT FOR OPTION A** | **SHOW TEXT FOR OPTION B** |

**[PROGRAMMER: KEEP “NO PREFERENCE” LAST]**

Q32\_C Which do you **prefer**?

Option A

Option B

No preference

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 2; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 2 Text (assigned) | Condition 7 Text (comparator) |
| DRUG Z is a biosimilar. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic.  DRUG Z is given the same way and has the same strength and dosage as the FDA-approved original biologic.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 3; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 3 Text (assigned) | Condition 7 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic.  DRUG Z is given the same way and has the same strength and dosage as the FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 4; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 4 Text (assigned) | Condition 7 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic.  DRUG Z is given the same way and has the same strength and dosage as the FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 5; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 5 Text (assigned) | Condition 7 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic.  DRUG Z is given the same way and has the same strength and dosage as the FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 6; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 6 Text (assigned) | Condition 7 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic.  DRUG Z is given the same way and has the same strength and dosage as the FDA-approved original biologic. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 7; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 7 Text (assigned) | Condition 6 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic.  DRUG Z is given the same way and has the same strength and dosage as the FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 8; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 8 Text (assigned) | Condition 6 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z is given the same way and has the same strength and dosage as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q. |

**[----------------------------------------New screen----------------------------------------]**

**[DISCLOSURE PREFERENCE #6]**

**[PROGRAMMER: RANDOMIZE THE TEXT BLOCK THAT IS ASSIGNED TO “OPTION A” AND “OPTION B”]**

|  |  |
| --- | --- |
| **OPTION A** | **OPTION B** |
| **SHOW TEXT FOR OPTION A** | **SHOW TEXT FOR OPTION B** |

**[PROGRAMMER: KEEP “NO PREFERENCE” LAST]**

Q33\_C Which do you **prefer**?

Option A

Option B

No preference

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 2; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 2 Text (assigned) | Condition 8 Text (comparator) |
| DRUG Z is a biosimilar. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z is given the same way and has the same strength and dosage as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 3; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 3 Text (assigned) | Condition 8 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z is given the same way and has the same strength and dosage as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 4; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 4 Text (assigned) | Condition 8 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z is given the same way and has the same strength and dosage as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 5; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 5 Text (assigned) | Condition 8 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z is given the same way and has the same strength and dosage as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 6; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 6 Text (assigned) | Condition 8 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z is given the same way and has the same strength and dosage as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 7; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 7 Text (assigned) | Condition 8 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic.  DRUG Z is given the same way and has the same strength and dosage as the FDA-approved original biologic. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z is given the same way and has the same strength and dosage as DRUG Q. |

**[PROGRAMMER: DISPLAY IF COHORT = 1 “CONSUMERS” AND XCONDITION = 8; DO NOT DISPLAY HIGHLIGHTED TEXT]**

|  |  |
| --- | --- |
| Condition 8 Text (assigned) | Condition 7 Text (comparator) |
| DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as DRUG Q, an FDA-approved original biologic.  This biosimilar is made from the same types of sources as DRUG Q.  DRUG Z is given the same way and has the same strength and dosage as DRUG Q. | DRUG Z is a biosimilar.  This biosimilar is a safe and effective medication and provides the same treatment benefits as an FDA-approved original biologic.  Biosimilars are made from the same types of sources as the FDA-approved original biologic.  DRUG Z is given the same way and has the same strength and dosage as the FDA-approved original biologic. |

**[----------------------------------------New screen----------------------------------------]**

**[BIOSIMILARS AWARENESS]**

Q34. Have you ever heard of biosimilars before today?

1 Yes

2 No

3 Don’t know

**[----------------------------------------New screen----------------------------------------]**

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP’ and Q34 = 1 ‘YES’]**

Q35\_P. How often do you prescribe biosimilars in your everyday clinical practice?

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 1  Never | 2  Rarely | 3  Sometimes | 4  Often | 5  All the time |

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’ and Q34 = 1 ‘YES’]**

Q35\_C. Have you ever taken a biosimilar product for any medical condition?

1 Yes

2 No

3 Don’t know

**[----------------------------------------New screen----------------------------------------]**

Q36. How much do you trust information provided by pharmaceutical companies about prescription drugs?

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| 1  Not at all | 2 | 3 | 4 | 5 | 6  A lot |

**[----------------------------------------New screen----------------------------------------]**

**[HEALTH LITERACY]**

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’]**

Q37\_C. How often do you need to have someone help you when you read instructions, pamphlets, or other written material from your doctor or pharmacy?

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 1  Never | 2  Rarely | 3  Sometimes | 4  Often | 5  Always |

**[----------------------------------------New screen----------------------------------------]**

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’]**

Q38\_C. Have you ever been diagnosed with rheumatoid arthritis?

1. Yes
2. No

Don’t know

**[----------------------------------------New screen----------------------------------------]**

**[PROGRAMMER: DISPLAY IF COHORT = 1 ‘CONSUMERS’ AND Q41\_C = 1 ‘YES’]**

Q39\_C. Have you ever taken a prescription drug for rheumatoid arthritis?

1. Yes, I am currently taking
2. Yes, I have in the past, but I am not currently taking
3. No, I have never taken

Don’t know

**[----------------------------------------New screen----------------------------------------]**

Q40. Have you ever seen any promotions for a biosimilar drug before today?

1 Yes

2 No

3 Unsure

**[----------------------------------------New screen----------------------------------------]**

**[# OF PRESCRIPTIONS/WEEK]**

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP’]**

Q41\_P. In a normal week, about how many prescriptions do you write? This includes both refills and new prescriptions. If you are not sure, please provide your best guess.

\_\_\_\_\_ prescriptions in a normal week

[**YEARS IN PRACTICE**]

**[PROGRAMMER: DISPLAY IF COHORT = 2 ‘HCP’]**

Q42\_P. Since completing your residency, how many years have you been a health care provider?

\_\_\_\_\_ years

**[----------------------------------------New screen----------------------------------------]**

**PRETEST FOLLOW-UP**

Q43. On a scale from 1-5, where 1 is completely negative and 5 is completely positive, how would you rate your experience with taking this survey?

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| 1  Completely Negative | 2 | 3 | 4 | 5  Completely positive |

Q44. Please tell us the main reasons for your rating score above.

[Open Field]

**DEBRIEF**

The purpose of this study is to learn about reactions to prescription drug information. [PROGRAMMER: IF XCONDITION = 3, 5, OR 7 DISPLAY “DRUG Z is not a real product and is not available for sale”; IF XCONDITION = 4, 6, OR 8 DISPLAY “DRUG Z and DRUG Q are not real products and are not available for sale”]. To get a real-life reaction, [PROGRAMMER: IF XCONDITION = 3, 5, OR 7 DISPLAY “we used a pretend product in this study”; IF XCONDITION = 4, 6, OR 8 DISPLAY “we used pretend products in this study”]. [PROGRAMMER: IF COHORT = 1 “CONSUMERS” DISPLAY Please see your health care professional for questions about rheumatoid arthritis.

You have been very helpful. Thank you very much for your participation!